MarketPeel
Insider Trading Intelligence
Pricing
…
CC

Christopher R. Cline

TVTX
CHIEF FINANCIAL OFFICER · TRAVERE THERAPEUTICS, INC. · CIK 0001943192
FILING MIX · LIFETIME38%/62%
BUYS
18
SELLS
30
TOTAL VALUE
$2.10M
COMPANIES
1
ACTIVE SINCE
Sep 2022
HOLDINGS NOW
118,658
AVG SELL PX
$29.63
TRADE KIND
SHOWING 48 / 48
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
27 backtested trades · 8 horizons · 48 pending
Forward-return performance of every backtestable P/S trade by Christopher R. Cline, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d27+51.85%+3.22%+0.88%+2.34%-1.95%—
14d27+51.85%+4.24%+1.45%+3.52%-1.29%—
30d27+44.44%+4.74%+2.52%+2.57%-1.64%—
60d27(1 pending)+38.46%+12.07%+3.09%+8.98%+4.45%—
90d27(6 pending)+47.62%+15.23%+4.81%+10.43%-3.07%—
180d27(9 pending)+38.89%+19.56%+10.42%+8.65%-1.03%—
1y27(13 pending)+35.71%+42.20%+21.68%+20.51%+47.42%—
2y27(19 pending)+37.50%+104.89%+43.51%+61.38%-8.16%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TVTX · 118,658 shares · as of May 6, 2026
031,30762,61393,920125,2262023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 18 buys / 30 sellsCOVERAGE · 16 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
310$43.95$13.6K118,658May 6, 2026May 6, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,181$46.65$101.7K118,968May 5, 2026May 6, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF FINANCIAL OFFICER
4,250——4,250May 4, 2026May 6, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
8,500——8,500May 4, 2026May 6, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASE
CHIEF FINANCIAL OFFICER
4,250——121,149May 4, 2026May 6, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,014$42.61$43.2K116,899Apr 15, 2026Apr 15, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
9$41.07$370125,152Apr 14, 2026Apr 15, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,239$41.93$303.5K117,913Apr 14, 2026Apr 15, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
65$28.85$1.9K125,161Apr 13, 2026Apr 15, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,000——125,226Apr 13, 2026Apr 15, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
110$32.90$3.6K111,226Feb 4, 2026Feb 4, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,635$32.14$52.5K111,336Feb 4, 2026Feb 4, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF FINANCIAL OFFICER
7,242$32.12$232.6K112,971Feb 3, 2026Feb 3, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
75,000——75,000Jan 31, 2026Feb 3, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
28,130——120,213Jan 31, 2026Feb 3, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASE
CHIEF FINANCIAL OFFICER
20,000$16.23$324.6K112,083Dec 1, 2025Dec 3, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
20,000$35.01$700.2K92,083Dec 1, 2025Dec 3, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF FINANCIAL OFFICER
20,000——0Dec 1, 2025Dec 3, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
119$19.71$2.3K92,083Sep 4, 2025Sep 5, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
454$18.20$8.3K92,202Sep 3, 2025Sep 5, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
470$17.31$8.1K92,656Aug 27, 2025Aug 28, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF FINANCIAL OFFICER
1,784$21.05$37.6K93,126May 5, 2025May 5, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASE
CHIEF FINANCIAL OFFICER
4,920——94,910May 2, 2025May 5, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF FINANCIAL OFFICER
4,920——4,920May 2, 2025May 5, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF FINANCIAL OFFICER
48$13.14$63189,990Apr 11, 2025Apr 14, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF FINANCIAL OFFICER
5,192$20.12$104.5K90,038Feb 3, 2025Feb 4, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
21,500——95,230Jan 31, 2025Feb 4, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
58,000——58,000Jan 31, 2025Feb 4, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF FINANCIAL OFFICER
865$18.94$16.4K73,730Jan 22, 2025Jan 23, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF FINANCIAL OFFICER
2,490$11.52$28.7K74,595Sep 9, 2024Sep 9, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,750——77,085Sep 5, 2024Sep 9, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF FINANCIAL OFFICER
514$9.51$4.9K70,335Sep 4, 2024Sep 5, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF FINANCIAL OFFICER
54$6.74$36470,849Apr 11, 2024Apr 12, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF FINANCIAL OFFICER
3,818$8.53$32.6K70,903Feb 1, 2024Feb 2, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——74,721Jan 31, 2024Feb 2, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
65,000——65,000Jan 31, 2024Feb 2, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF FINANCIAL OFFICER
853$9.07$7.7K49,721Jan 23, 2024Jan 25, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Financial Officer
457$14.71$6.7K50,574Sep 5, 2023Sep 5, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Financial Officer
455$16.59$7.5K51,031May 10, 2023May 12, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Financial Officer
47$21.49$1.0K51,486Apr 11, 2023Apr 13, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Financial Officer
1,588$21.75$34.5K51,533Feb 1, 2023Feb 2, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
54,500——54,500Jan 31, 2023Feb 2, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,250——53,121Jan 31, 2023Feb 2, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,750——6,750Jan 31, 2023Feb 2, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Financial Officer
852$21.90$18.7K32,871Jan 24, 2023Jan 26, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,000——33,723Sep 1, 2022Sep 1, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
48,000——48,000Sep 1, 2022Sep 1, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,840——9,840Sep 1, 2022Sep 1, 2022 ↗View →
Other insiders · TVTX
Loading peer insiders…
About this filer
CIK 0001943192
ROLE
CHIEF FINANCIAL OFFICER
PRIMARY
TVTX
COMPANIES
1
ACTIVE SINCE
Sep 2022
MARKETPEEL · /INSIDER/0001943192DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback